Literature DB >> 25551302

Plasma cholesterol in adults with phenylketonuria.

Robin A Williams1, Amanda J Hooper, Damon A Bell, Cyril D S Mamotte, John R Burnett.   

Abstract

Phenylketonuria (PKU) is an autosomal recessive disorder of phenylalanine (Phe) catabolism resulting from a deficiency of L-phenylalanine hydroxylase (PAH). An association between hyperphenylalaninaemia (HPA) and hypocholesterolaemia has been reported in children. However, controversy exists as to whether this is due to the low protein diet or to a disruption to cholesterol biosynthesis inherent to those with PKU. We investigated the relationship between blood Phe and plasma cholesterol in 41 apparently healthy adults with PKU (26 female, 15 male, age 18-57 years, median age 26 years) attending a PKU outpatient clinic at an adult tertiary care hospital. Of these patients, 33 (80%) were compliant with a Phe-restricted diet with amino acid supplementation, whereas eight (20%) were not. The PKU subjects had a mean body mass index (BMI) of 30.3 ± 1.8 kg/m; 72% were obese, 14% overweight, with only 14% having normal BMI. The mean blood Phe was 1194 ± 522 μmol/L with plasma total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol and apolipoprotein (apo) B concentrations of 4.3 ± 0.8 mmol/L, 1.6 ± 0.8 mmol/L, 1.2 ± 0.3 mmol/L, 2.3 ± 0.8 mmol/L, and 0.83 ± 0.21 g/L, respectively. The mean LDL-cholesterol was 19% lower in PKU females than that of 8944 age-matched females from a community population (2.5 ± 0.8 mmol/L vs. 3.1 ± 0.9 mmol/L, p < 0.001). Similarly, the mean LDL-cholesterol was 32% lower in PKU males than 3786 age-matched males (2.1 ± 0.7 mmol/L vs. 3.1 ± 1.0 mmol/L, p < 0.0001). No correlations were observed between Phe and total cholesterol, LDL-cholesterol or apoB in the PKU cohort. Adults with PKU had low-normal cholesterol concentrations, with no correlation observed between Phe and cholesterol levels. Our findings support the concept that the HPA found in PKU, rather than an effect of a low-protein diet, leads to hypocholesterolaemia. Studies are required to determine whether this cholesterol-lowering effect confers cardioprotection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25551302     DOI: 10.1097/PAT.0000000000000210

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities - a retrospective study of German health insurance claims data.

Authors:  K F Trefz; A C Muntau; K M Kohlscheen; J Altevers; C Jacob; S Braun; W Greiner; A Jha; M Jain; I Alvarez; P Lane; C Schröder; F Rutsch
Journal:  Orphanet J Rare Dis       Date:  2019-07-22       Impact factor: 4.123

2.  CRISPR/Cas9 generated knockout mice lacking phenylalanine hydroxylase protein as a novel preclinical model for human phenylketonuria.

Authors:  Kuldeep Singh; Cathleen S Cornell; Robert Jackson; Mostafa Kabiri; Michael Phipps; Mitul Desai; Robert Fogle; Xiaoyou Ying; Gulbenk Anarat-Cappillino; Sarah Geller; Jennifer Johnson; Errin Roberts; Katie Malley; Tim Devlin; Matthew DeRiso; Patricia Berthelette; Yao V Zhang; Susan Ryan; Srinivas Rao; Beth L Thurberg; Dinesh S Bangari; Sirkka Kyostio-Moore
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

3.  Dietetic Management of Adults with Phenylketonuria (PKU) in the UK: A Care Consensus Document.

Authors:  Louise Robertson; Sarah Adam; Charlotte Ellerton; Suzanne Ford; Melanie Hill; Gemma Randles; Alison Woodall; Carla Young; Anita MacDonald
Journal:  Nutrients       Date:  2022-01-28       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.